{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:24:25Z","timestamp":1777623865196,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15861-2","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:44:03Z","timestamp":1773891843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Shanqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"15861_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49.","journal-title":"Signal Transduct Target Ther"},{"key":"15861_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.20.25223","volume":"217","author":"DC Teichgraeber","year":"2021","unstructured":"Teichgraeber DC, Guirguis MS, Whitman GJ. Breast cancer staging: updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. AJR Am J Roentgenol. 2021;217:278\u201390.","journal-title":"AJR Am J Roentgenol"},{"key":"15861_CR3","doi-asserted-by":"publisher","first-page":"2461234","DOI":"10.1155\/tbj\/2461234","volume":"2025","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, Wuerstlein R, Aruga T, Haidinger R, Lambertini M, Benjamin C, et al. Underserved patient populations with metastatic breast cancer: a review of progress and remaining challenges. Breast J. 2025;2025:2461234.","journal-title":"Breast J"},{"key":"15861_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"15861_CR5","doi-asserted-by":"publisher","first-page":"115164","DOI":"10.1016\/j.ejca.2024.115164","volume":"215","author":"M Milano","year":"2025","unstructured":"Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, et al. Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer. Eur J Cancer. 2025;215:115164.","journal-title":"Eur J Cancer"},{"key":"15861_CR6","doi-asserted-by":"publisher","first-page":"103839","DOI":"10.1016\/j.breast.2024.103839","volume":"79","author":"RR Colciago","year":"2025","unstructured":"Colciago RR, De Santis MC, Giandini C, Carnevale MG, Di Cosimo S. Treatment of oligometastatic breast cancer: the role of patient selection. Breast. 2025;79:103839.","journal-title":"Breast"},{"key":"15861_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s10147-025-02776-4","volume":"30","author":"N Imano","year":"2025","unstructured":"Imano N. Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives. Int J Clin Oncol. 2025;30:1505\u201321.","journal-title":"Int J Clin Oncol"},{"key":"15861_CR8","doi-asserted-by":"publisher","first-page":"1243053","DOI":"10.3389\/fonc.2023.1243053","volume":"13","author":"JS Kim","year":"2023","unstructured":"Kim JS, Chang AR. Abscopal effect in metastatic breast cancer treated with stereotactic body radiotherapy in the absence of immunotherapy. Front Oncol. 2023;13:1243053.","journal-title":"Front Oncol"},{"key":"15861_CR9","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/cancers17142406","volume":"17","author":"T Shien","year":"2025","unstructured":"Shien T, Nakamoto S, Fujiwara Y, Kosaka M, Narahara Y, Fujii K, et al. Definitions of, advances in, and treatment strategies for breast cancer oligometastasis. Cancers (Basel). 2025;17:2406.","journal-title":"Cancers (Basel)"},{"key":"15861_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cam4.5021","volume":"12","author":"H Sun","year":"2023","unstructured":"Sun H, Xu J, Dai S, Ma Y, Sun T. Breast cancer brain metastasis: current evidence and future directions. Cancer Med. 2023;12:1007\u201324.","journal-title":"Cancer Med"},{"key":"15861_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"key":"15861_CR12","doi-asserted-by":"publisher","first-page":"5027457","DOI":"10.1155\/2022\/5027457","volume":"2022","author":"H Lin","year":"2022","unstructured":"Lin H, Lin J, Wu Y, Liang G, Sun J, Chen L. Exploring the prognosis of breast cancer with synchronous distant nonregional lymph node metastasis and establishing a predictive model: a population-based study. Biomed Res Int. 2022;2022:5027457.","journal-title":"Biomed Res Int"},{"key":"15861_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.breast.2022.12.007","volume":"67","author":"A van Ommen-Nijhof","year":"2023","unstructured":"van Ommen-Nijhof A, Steenbruggen TG, Capel L, Vergouwen M, VranckenPeeters MT, Wiersma TG, et al. Survival and prognostic factors in oligometastatic breast cancer. Breast. 2023;67:14\u201320.","journal-title":"Breast"},{"key":"15861_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/ijc.33152","volume":"147","author":"B Lan","year":"2020","unstructured":"Lan B, Abudureheiyimu N, Zhang J, Wang C, Jiang S, Wang J, et al. Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. Int J Cancer. 2020;147:3199\u2013205.","journal-title":"Int J Cancer"},{"key":"15861_CR15","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1002\/cncr.30058","volume":"122","author":"AC Wong","year":"2016","unstructured":"Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122:2242\u201350.","journal-title":"Cancer"},{"key":"15861_CR16","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.ctrv.2020.102114","volume":"91","author":"A van Ommen-Nijhof","year":"2020","unstructured":"van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, Mann R, et al. Prognostic factors in patients with oligometastatic breast cancer - a systematic review. Cancer Treat Rev. 2020;91:102114.","journal-title":"Cancer Treat Rev"},{"key":"15861_CR17","doi-asserted-by":"publisher","first-page":"pkab010","DOI":"10.1093\/jncics\/pkab010","volume":"5","author":"TG Steenbruggen","year":"2021","unstructured":"Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, et al. Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de novo metastatic breast cancer. JNCI Cancer Spectr. 2021;5:pkab010.","journal-title":"JNCI Cancer Spectr"},{"key":"15861_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000503847","volume":"15","author":"C Cha","year":"2020","unstructured":"Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, et al. Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. Breast Care (Basel). 2020;15:408\u201314.","journal-title":"Breast Care (Basel)"},{"key":"15861_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00066-022-01938-x","volume":"198","author":"MD Piroth","year":"2022","unstructured":"Piroth MD, Krug D, Feyer P, Baumann R, Combs S, Duma MN, et al. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective. Strahlenther Onkol. 2022;198:601\u201311.","journal-title":"Strahlenther Onkol"},{"key":"15861_CR20","doi-asserted-by":"publisher","first-page":"102462","DOI":"10.1016\/j.ctrv.2022.102462","volume":"110","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Visani L, Marini S, Griguolo G, Vernaci GM, Bottosso M, et al. Oligometastatic breast cancer: dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? Cancer Treat Rev. 2022;110:102462.","journal-title":"Cancer Treat Rev"},{"key":"15861_CR21","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S1470-2045(23)00286-3","volume":"24","author":"D Pasquier","year":"2023","unstructured":"Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, et al. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. Lancet Oncol. 2023;24:e331\u201343.","journal-title":"Lancet Oncol"},{"key":"15861_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12282-023-01436-7","volume":"30","author":"S Imoto","year":"2023","unstructured":"Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast Cancer. 2023;30:412\u201323.","journal-title":"Breast Cancer"},{"key":"15861_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10549-023-06880-9","volume":"198","author":"JL Lacaze","year":"2023","unstructured":"Lacaze JL, Chira C, Glemarec G, Monselet N, Cassou-Mounat T, De Maio E, et al. Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution. Breast Cancer Res Treat. 2023;198:463\u201374.","journal-title":"Breast Cancer Res Treat"},{"key":"15861_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11912-024-01529-2","volume":"26","author":"SM Yoon","year":"2024","unstructured":"Yoon SM, Bazan JG. Navigating breast cancer oligometastasis and oligoprogression: current landscape and future Directions. Curr Oncol Rep. 2024;26:647\u201364.","journal-title":"Curr Oncol Rep"},{"key":"15861_CR25","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138.","journal-title":"Lancet"},{"key":"15861_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","volume":"7","author":"S Chmura","year":"2021","unstructured":"Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, et al. Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial. JAMA Oncol. 2021;7:845\u201352.","journal-title":"JAMA Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15861-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15861-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:04:42Z","timestamp":1777417482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15861-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15861"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15861-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Zhengzhou University Institutional Research Committee, and written informed consent for medical research was obtained from all patients prior to initial treatment. All methods were performed in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}